Middeke J.M., Beelen D., Stadler M., Gohring G., Schlegelberger B., Baurmann H., et al. <...> Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. <...> Breems D.A., van Putten W.L.J., Lowenberg B. The impact of abn(17p) and monosomy 25/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. <...> IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. <...> Cluzeau T., Mounier N., Karsenti J.M., Richez V., Legros L., Gastaud L., et al. <...> Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with azacitidine. <...> Pleyer L., Burgstaller S., Girschikofsky M., Linkesch W., Stauder R., Pfeilstocker M., et al. <...> Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. <...> Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <...> Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. <...> Time from diagnosis to treatment initiation premonosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. <...> Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <...> High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: updated analyses from Eastern Cooperative Oncology trial E1900. <...> FLAG-IDA has significant activity as frontline induction or salvage therapy for patients with high risk and/or relapsed or refractory acute myeloid leukemia. <...> Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. <...> Azacitidine versus conventional care regimens in older patients with newly diagnosed acute myeloid leukemia (>30% bone marrow blasts) with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial. <...> Zeidan A.M., Gore S.D., Komrokji R.S. Higher-risk myelodysplastic syndromes with del(5q <...>